Does low bioavailable testosterone in men increase risk of insulin resistance, metabolic syndrome, and type 2 diabetes?

Low testosterone levels in men are a well-documented risk factor for the development of metabolic disorders. The relationship between bioavailable testosterone—the fraction of the hormone not bound to Sex Hormone-Binding Globulin (SHBG)—and metabolic health is complex, involving bidirectional influences between androgen signaling and insulin regulation.

Clinical and Metabolic Evidence

Extensive longitudinal research confirms that low bioavailable and free testosterone levels significantly predict the future onset of metabolic syndrome (MetS) and type 2 diabetes (T2D).

• Disease Risk: Men in the lowest quartiles of testosterone have a substantially higher risk of incident MetS and T2D. For example, the T4DM trial demonstrated that testosterone treatment in men with low levels and prediabetes reduced the progression to T2D by 40% (RR 0.59, 95% CI 0.48–0.73) over two years when combined with lifestyle interventions.
• Insulin Sensitivity: Low bioavailable testosterone is strongly associated with higher HOMA-IR scores, indicating reduced insulin sensitivity. Conversely, improving testosterone levels has been shown to enhance glucose uptake in skeletal muscle and reduce systemic inflammation.

Mechanistic Explanations

The link between low testosterone and metabolic dysfunction is driven by specific physiological pathways:

• Adipose Tissue Regulation: Testosterone exerts an anti-adipogenic effect, inhibiting the differentiation of pre-adipocytes into mature fat cells. Low levels lead to increased visceral adiposity, which secretes pro-inflammatory cytokines (e.g., TNF-α, IL-6) that directly impair insulin signaling.
• The SHBG Paradox: While the claim suggests high SHBG leads to low bioavailable testosterone, the metabolic reality is often the opposite. High insulin levels typically suppress hepatic SHBG production. Consequently, men with insulin resistance and MetS often present with low SHBG and low total testosterone, which further reduces the bioavailable fraction.
• Skeletal Muscle Metabolism: Testosterone increases the expression of GLUT4 glucose transporters and key glycolytic enzymes in skeletal muscle, the primary site for glucose disposal.

Bottom line

The claim that low bioavailable testosterone is associated with reduced insulin sensitivity and a higher risk of metabolic syndrome and type 2 diabetes is strongly supported by clinical and mechanistic evidence. While high SHBG can reduce bioavailable testosterone, most insulin-resistant states are actually characterized by low SHBG; however, the resulting reduction in androgen signaling remains a primary driver of metabolic decline.